

NEWS RELEASE FEBRUARY 3, 2022

## Entheon Biomedical Announces the Approval of DMT Clinical Trial

PR, British Columbia--(Newsfile Corp. - February 03, 2022) - Entheon Biomedical Corp. (CSE: ENBI) ENTBF) (FSE: 1XU1) ("**Entheon**" or the "**Company**"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, announced today the approval by the local Dutch ethics committee of EBRX-101, a large phase I clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of dimethyltryptamine (DMT). The study will be conducted at the Centre for Human Drug Research, in Amsterdam, Netherlands, with patient screening scheduled to begin this month.

EBRX-101 study is the core research focus of Entheon Rx™, one of the Company's business divisions, focused on advancing the therapeutic potential of DMT and DMT-based drug analogues. The study uses an adaptive, randomized, double-blind, placebo-controlled design with a single ascending dose of DMT to be administered via continuous-controlled infusion to a population of otherwise healthy individuals. This phase 1 study will provide Entheon with essential safety and dosing data, providing the foundation for further research of DMT's therapeutic potential.

"DMT's unique metabolic and neuroprotective properties, together with its record of safe human use in the literature, suggests that it is an ideal candidate for therapeutic administration," says Dr. Andrew Glassen, Chief Science Officer of Entheon. "However, it is crucial that we thoroughly investigate the pharmacological properties and safety profile of infused DMT in a clinical setting, and fully characterize its effects on the central nervous system. These results will form the basis for Entheon's phase 2 efficacy trials for the cessation and the treatment of other substance use disorders."

"DMT is a classic hallucinogen, similar to LSD or psilocybin in that it exerts many of its subjective, visual, and auditory therapeutic effects via the brain's serotonin system. DMT differs from the other serotonergic psychedelics in that it is naturally found in the body in trace amounts, and when given externally is rapidly metabolized, with subjective effects returning to baseline after roughly thirty minutes post-administration.

"The completion of this study is a significant achievement for the company, marking the culmination of months of work," says Timothy Ko, CEO of Entheon. "In our estimation and based on our review of existing literature, EBRX-101 is the most comprehensive studies of DMT to date. This clinical trial will serve as a benchmark for further investigation into the development of DMT as a treatment for addiction disorders."

### Entheon Biomedical Corp.

Entheon is a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders. Entheon is comprised of three divisions: Entheon RX™, focused on the development of therapeutic drugs, using N, N-dimethyltryptamine (**DMT**) as the pharmacological benchmark; Entheon ID™, focused on identification, and predictive use of EEG biomarkers and genetics in the selection and management of drug addiction; and Entheon IQ™, focused on the development of treatment algorithms through the analysis of patient data. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States and certain countries in the European Union and throughout Canada.

### For more information, please contact the Company at:

Entheon Biomedical Corp.  
Attention: Investor Relations  
Phone: +1 (778) 919-8615  
Email: [investor@entheonbiomedical.com](mailto:investor@entheonbiomedical.com)  
Website: [entheonbiomedical.com/](http://entheonbiomedical.com/)

### For all inquiries, please contact Elizabeth Glassen of BlueSky Communications at:

BlueSky Communications  
Elizabeth Glassen, Account Manager  
Phone: +1 (647) 309-0141  
Email: [elizabeth@blueskycommunications.com](mailto:elizabeth@blueskycommunications.com)

### Forward-Looking Information

## RECENT RELEASES

FEBRUARY 3, 2022

**Entheon Biomedical Announces the Approval of DMT Clinical Trial**

JANUARY 18, 2022

**Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today**

JANUARY 18, 2022

**Entheon Biomedical Corp. Files Preliminary Shelf Prospectus**

JANUARY 6, 2022

**Entheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory Submission to Ethics Committee**

DECEMBER 21, 2021

**Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel**

ase 1 trial will be sufficient for a phase 2 trial and other matters. The forward-looking statements  
mation are based on certain key expectations and assumptions made by management of the  
, including, but not limited to, assumptions relating to the continued impact and status of COVID on  
any's personnel and planned research activities, that general economic and political conditions will  
he same, stability in applicable law and regulations and that future studies will occur. Although  
nent of the Company believes that the expectations and assumptions on which such forward-looking  
ts and information are based are reasonable, undue reliance should not be placed on the forward-  
tatemnts and information since no assurance can be given that they will prove to be correct.

looking statements and information are provided for the purpose of providing information about the  
xpectations and plans of management of the Company relating to the future. Readers are cautioned  
nce on such statements and information may not be appropriate for other purposes, such as making  
nt decisions. Since forward-looking statements and information address future events and  
s, by their very nature they involve inherent risks and uncertainties. Actual results could differ  
y from those currently anticipated due to a number of factors and risks. Accordingly, readers should  
undue reliance on the forward-looking statements and information contained in this news release.  
are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements and  
on contained in this news release are made as of the date hereof and no undertaking is given to  
ublicly or revise any forward-looking statements or information, whether as a result of new  
on, future events or otherwise, unless so required by applicable securities laws. The forward-looking  
ts or information contained in this news release are expressly qualified by this cautionary statement.

he CSE nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the  
r or accuracy of this release.

re source version of this press release, please visit <https://www.newsfilecorp.com/release/112651>

[Releases](#)